Cargando…

Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis

Several second-generation bisphosphonates (BPs) are approved in osteoporosis treatment. Efficacy and safety depends on potency of farnesyl pyrophosphate synthase (FPPS) inhibition, hydroxyapatite affinity, compliance and adherence. The latter may be influenced by frequency and route of administratio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inderjeeth, Charles A, Glendenning, Paul, Ratnagobal, Shoba, Inderjeeth, Diren Che, Ondhia, Chandni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274146/ https://www.ncbi.nlm.nih.gov/pubmed/25565901 http://dx.doi.org/10.2147/IJWH.S73944

Ejemplares similares

Efficacy, safety, and compliance of ibandronate treatment for 3 years in postmenopausal Japanese women with primary osteoporosis
por: Suzuki, Takako, et al.
Publicado: (2018)

Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women
por: Sambrook, Philip
Publicado: (2007)

Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis
por: Bauss, Frieder, et al.
Publicado: (2006)

Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis
por: Uehara, Masashi, et al.
Publicado: (2021)

Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis
por: Nakamura, T., et al.
Publicado: (2015)

Evidence for the Treatment of Osteoporosis with Vitamin D in Residential Care and in the Community Dwelling Elderly
por: Geddes, John A. A., et al.
Publicado: (2013)

Efficacy and Safety of Monthly 150 mg Oral Ibandronate in Women with Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Lee, Young Ho, et al.
Publicado: (2011)

Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis
por: Ma, Zeren, et al.
Publicado: (2016)

Efficacy of a Once-Monthly Pill Containing Ibandronate and Cholecalciferol on the Levels of 25-Hydroxyvitamin D and Bone Markers in Postmenopausal Women with Osteoporosis
por: Cho, In-Jin, et al.
Publicado: (2015)

Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update
por: Messalli, Enrico M, et al.
Publicado: (2010)

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
por: Pazianas, Michael, et al.
Publicado: (2010)

Systemic juvenile idiopathic arthritis: frequency and long-term outcome in Western Australia
por: Nossent, Johannes C., et al.
Publicado: (2023)

Dose-Effectiveness Relationships Determining the Efficacy of Ibandronate for Management of Osteoporosis: A Meta-Analysis
por: Hou, Yanjie, et al.
Publicado: (2015)

Long-Term Risk of Comorbidity after IgA Vasculitis in Childhood: A Population-Based Cohort Study
por: Nossent, Johannes, et al.
Publicado: (2020)

Efficacy and safety of bazedoxifene for postmenopausal osteoporosis
por: Kawate, Hisaya, et al.
Publicado: (2011)

Adult‐onset Still's disease in Western Australia: Epidemiology, comorbidity and long‐term outcome
por: Nossent, Johannes, et al.
Publicado: (2022)

Long-Term Treatment of Postmenopausal Osteoporosis
por: Brown, Jacques P.
Publicado: (2021)

A prospective comparative study of intravenous alendronate and ibandronate for the treatment of osteoporosis
por: Horikawa, Akira, et al.
Publicado: (2019)

Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis
por: Dore, Robin K
Publicado: (2013)

Osteoprotegerin genetic polymorphisms and their influence on therapeutic response to ibandronate in postmenopausal osteoporotic females
por: Tariq, Saba, et al.
Publicado: (2023)

Management Challenges in Atypical Femoral Fractures: A Case Report
por: Golsorkhtabaramiri, Mohammad, et al.
Publicado: (2020)

Safety and effectiveness of monthly intravenous ibandronate injections in a prospective, postmarketing, and observational study in Japanese patients with osteoporosis
por: Takeuchi, Yasuhiro, et al.
Publicado: (2018)

Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis
por: Nakamura, Yumejiro, et al.
Publicado: (2021)

Limited referral to nephrologists from a tertiary geriatric outpatient clinic despite a high prevalence of chronic kidney disease and anaemia
por: Boudville, Neil, et al.
Publicado: (2012)

Effects of eldecalcitol and ibandronate on secondary osteoporosis and muscle wasting in rats with adjuvant-induced arthritis
por: Ono, Yuichi, et al.
Publicado: (2018)

Effect of lumbar spinal stenosis on bone mineral density in osteoporosis patients treated with ibandronate
por: Park, Hyung-Youl, et al.
Publicado: (2021)

Comparison of effectiveness and safety of ibandronate and minodronate combined with eldecalcitol in primary osteoporosis of women: A 1-year follow-up study
por: Tanaka, Mizue, et al.
Publicado: (2017)

The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties
por: Nakai, Kiyohiko, et al.
Publicado: (2014)

Effect of Ibandronate Therapy on Serum Chemerin, Vaspin, Omentin-1 and Osteoprotegerin (OPG) in Postmenopausal Osteoporotic Females
por: Tariq, Saba, et al.
Publicado: (2022)

Incidence and Complication Rates for Total Hip Arthroplasty in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Across Four Decades
por: Taylor-Williams, Owen, et al.
Publicado: (2020)

Efficacy and Safety of Denosumab in Postmenopausal Women With Osteoporosis: A Meta-Analysis
por: Gu, Hai-Feng, et al.
Publicado: (2015)

Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid
por: Li, Edmund K, et al.
Publicado: (2010)

Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
por: Anastasilakis, Athanasios D, et al.
Publicado: (2012)

Efficacy and Mechanisms of Oleuropein in Postmenopausal Osteoporosis
por: Liu, Huilan, et al.
Publicado: (2022)

Ibandronate Treatment Before and After Implant Insertion Impairs Osseointegration in Aged Rats with Ovariectomy Induced Osteoporosis
por: Lotz, Ethan M., et al.
Publicado: (2019)

Effect of Frailty on Functional Gain, Resource Utilisation, and Discharge Destination: An Observational Prospective Study in a GEM Ward
por: Kawryshanker, Sujatha, et al.
Publicado: (2014)

Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
por: Chen, Yi, et al.
Publicado: (2021)

Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2011)

SOCIODEMOGRAPHIC FACTORS AFFECTING THE DISEASE ACCEPTANCE IN THE GROUP OF WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS
por: Górczewska, Bogumiła, et al.
Publicado: (2022)

Retrospective analysis of the clinical course of patients treated for polymyalgia
por: Do-Nguyen, Dung, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_sq2oj5l8p1ilmqmou2cbpkugp7